Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.81 |
| ▸ | THRB | P10828 | 8/20 | 0.81 |
| ▸ | BLM | P54132 | 7/20 | 0.81 |
| ▸ | RECQL | P46063 | 6/20 | 0.81 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.81 |
| ▸ | TOP2A | P11388 | 5/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.81 |
| ▸ | HTT | P42858 | 4/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.81 |
| ▸ | STAT6 | P42226 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43830 | 0.96 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL1771543 | 0.95 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL27900762 | 0.95 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL272961 | 0.95 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL22409662 | 0.94 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL16318978 | 0.94 | MEN1 (0.84) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL27834123 | 0.94 | MEN1 (0.91) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL29048581 | 0.93 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL147968 | 0.93 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL29048586 | 0.93 | MEN1 (0.81) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112480289-B | Core-shell structure type chitosan-based nano prodrug carrying doxorubicin and platinum drugs together, and preparation method and application thereof | 西安交通大学 | 2021-09-07 | — | — | CN | claimed |
| CN-112480289-A | Core-shell structure type chitosan-based nano prodrug carrying doxorubicin and platinum drugs together, and preparation method and application thereof | 西安交通大学 | 2021-03-12 | — | — | CN | claimed |
| US-20210023017-A1 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | UNIV MASSACHUSETTS (US) | 2021-01-28 | — | — | US | claimed |
| EP-3765089-A1 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | University of Massachusetts (US) | 2021-01-20 | — | — | EP | claimed |
| WO-2019178443-A1 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | UNIVERSITY OF MASSACHUSETTS (US) | 2019-09-19 | — | — | WO | claimed |
| US-20230372534-A1 | CONJUGATES OF ACTIVE PHARMACEUTICAL INGREDIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-23 | — | — | US | disclosed |
| WO-2023129652-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | SCOTT, JOHN KIM, JR. | 2023-07-06 | — | — | US | disclosed |
| WO-2023107574-A2 | LIPID-BASED COMPOSITIONS AND METHODS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11559585-B2 | Conjugates of active pharmaceutical ingredients | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220401562-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-22 | — | — | US | disclosed |
| CN-112480289-B | Core-shell structure type chitosan-based nano prodrug carrying doxorubicin and platinum drugs together, and preparation method and application thereof | 西安交通大学 | 2021-09-07 | — | — | CN | disclosed |
| EP-3125866-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | President and Fellows of Harvard College (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160220686-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | disclosed |
| US-20160114046-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | disclosed |
| WO-2015154082-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-1691664-A4 | ANTIBODIES AND/OR CONJUGATES THEREOF WHICH BIND TO THE AMINO TERMINAL FRAGMENT OF UROKINASE, COMPOSITIONS AND USES THEREOF | ATTENUON LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1691664-A2 | ANTIBODIES AND/OR CONJUGATES THEREOF WHICH BIND TO THE AMINO TERMINAL FRAGMENT OF UROKINASE, COMPOSITIONS AND USES THEREOF | Attenuon, LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050232924-A1 | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof | ATTENUON LLC | 2005-10-20 | — | — | US | disclosed |
| WO-2005048822-A2 | ANTIBODIES AND/OR CONJUGATES THEREOF WHICH BIND TO THE AMINO TERMINAL FRAGMENT OF UROKINASE, COMPOSITIONS AND USES THEREOF | ATTENUON LLC (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | TOP1, ALG1, GNE | MEN1 1618/4885KMT2A 2242/4885THRB 4381/4885 |
| US-20160220686-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | LDLR, LIPA, ABCB11 | MEN1 3323/4885KMT2A 4459/4885THRB 2873/4885 |
| US-11559585-B2 | Conjugates of active pharmaceutical ingredients | CD47, CD63, TFRC | MEN1 973/4885KMT2A 2214/4885THRB 3167/4885 |
| US-20220401562-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | LDLR, LIPA, ABCB11 | MEN1 3323/4885KMT2A 4459/4885THRB 2873/4885 |
| US-20160114046-A1 | REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | LDLR, LIPA, ABCB11 | MEN1 3323/4885KMT2A 4459/4885THRB 2873/4885 |
| US-20050232924-A1 | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof | PLAU, PLAUR, DNPEP | MEN1 1542/4885KMT2A 3056/4885THRB 1679/4885 |
| US-20230372534-A1 | CONJUGATES OF ACTIVE PHARMACEUTICAL INGREDIENTS | CD47, CD63, TFRC | MEN1 973/4885KMT2A 2214/4885THRB 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.